<DOC>
	<DOCNO>NCT00895102</DOCNO>
	<brief_summary>The purpose study determine bioavailability , pharmacokinetic safety profile experimental Hepatitis C virus ( HCV ) polymerase inhibitor healthy volunteer .</brief_summary>
	<brief_title>Bioavailability ABT-333 Tablet Versus First Human ( FIH ) Capsule Formulation Safety , Tolerability PK Study Single Doses ABT-333 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>overall healthy subject ; nonchildbearing potential female include history significant sensitivity drug ; positive test HAV IgM , HBsAg , antiHCV Ab antiHIV Ab ; history gastrointestinal issue procedure ; history seizure , diabetes cancer ( except basal cell carcinoma ) ; clinically significant cardiovascular , respiratory ( except mild asthma ) , renal , gastrointestinal , hematologic , neurologic , thyroid , uncontrolled medical illness psychiatric disorder ; use tobacco nicotinecontaining product 6month period prior study drug administration ; donation loss 550 mL blood volume receipt transfusion blood product within 8 week prior study drug administration ; abnormal screen laboratory result consider clinically significant investigator ; current enrollment another clinical study ; previous enrollment study ; recent ( 6month ) history drug/alcohol abuse could preclude adherence protocol ; pregnant breastfeeding female ; requirement OTC and/or prescription medication , vitamins and/or herbal supplement regular basis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Bioavailability ( BA )</keyword>
	<keyword>Single Ascending Dose ( SAD )</keyword>
</DOC>